Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

EP: 1.CAR T-cell Therapy for B-ALL

EP: 2.Navigating Treatment Selections for B-ALL: Insights From the Moffitt Cancer Center

EP: 3.The Multidisciplinary Approach to CAR T-Cell Therapy for B-ALL

EP: 4.CAR T-Cell Therapy for B-ALL: Roles Within the Multidisciplinary Care Team

EP: 5.Optimizing Molecular Profiling for B-ALL Treatment

EP: 6.Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL

EP: 7.Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment

EP: 8.Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission

EP: 9.CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment

Now Viewing

EP: 10.Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

EP: 11.Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

EP: 12.Future Considerations for Treatment Sequencing in B-ALL

Video content above is prompted by the following:

In general, what has been your combined experience with CRS, ICANS, and other immunotoxicities post CAR T-cell therapy?

At Moffitt Cancer Center, do you implement a standardized protocol to address and resolve cell therapy–associated immunotoxicities and adverse events?

• How do you modify your interventions across grades of severity?
• Do you employ any prophylactic mitigation strategies before or during CAR T-cell infusion to attenuate the risk and/or severity of treatment-related adverse events?
• At your center, who on the multidisciplinary team participates in patient monitoring during the initial 30 days post CAR T-cell therapy?
• How is the patient monitored and who monitors them during the longer-term postinfusion period?